| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-10 |
| filingDate |
2000-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21c8587b55b3cc44365cbff8557f8fef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee851c29a4a2952758979909a315e750
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff50a158bd330421df1314c742438372
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d8280231a952bb395cc9daf9758489c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85058eb89c4928006f01e03741188026 |
| publicationDate |
2001-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2355456-A |
| titleOfInvention |
Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| abstract |
Novel arylhydantoin derivatives of the formula shown in claim 1 and their pharmaceutically acceptable salts have been found to exhibit activity against benign prostatic hyperplasia (BPH). Compounds of this kind are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without simultaneously inducing hypotension. Such tissue is found surrounding the urethral lining. Thus treatment with the said compounds offers relief to males suffering from BPH by permitting less hindered urine flow. The said derivatives may also be used in conjunction with human 5-alpha reductase inhibitor compounds in the treatment of both acute and chronic BPH. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8263605-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7696201-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7858635-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7858790-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005090316-A1 |
| priorityDate |
1999-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |